Results 31 to 40 of about 3,972 (148)

Larotrectinib as an Effective Therapy in Congenital Infantile Fibrosarcoma: Report of Two Cases

European Journal of Pediatric Surgery Reports, 2022
Congenital infantile fibrosarcoma (CIF) is a rare tumor in children that occurs in the first years of life. It usually arises in the extremities but some cases affect the trunk, neck, abdomen, or retroperitoneum. Surgical resection has been traditionally
Lucas Moratilla Lapeña, Maria Carmen Sarmiento Caldas, Carla Ramírez, María San Basilio, Paloma Triana Junco, Lara Rodríguez-Laguna, Victor Martínez-González, Elena Marín-Manzano, Antonio Perez-Martinez, Juan Carlos Lopez-Gutierrez   +9 more
doaj   +1 more source

TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report

Current Oncology, 2022
NTRK gene fusions are rare oncogenic driver mutations that can be found in a broad range of neoplasms. In secretory carcinoma (SC), ETV6-NTRK3 gene fusion is seen in a majority of the cases and represents a druggable target for patients with advanced ...
Matthew S. Ernst, John T. Lysack, Martin D. Hyrcza, Shamir P. Chandarana, Desiree Hao   +4 more
doaj   +1 more source

Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers

Journal of Hematology & Oncology, 2018
Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell ...
Yu Chen, Ping Chi
doaj   +1 more source

Larotrectinib treatment for infantile fibrosarcoma in newborns: a case report and literature review

Frontiers in Oncology, 2023
Infantile fibrosarcoma (IFS) is a rare tumor in childhood characterized by a single, localized, painless mass that grows rapidly but has a relatively indolent biological behavior and a favorable prognosis.
Dandan Wang, Dandan Wang, Fanhui Zhang, Fanhui Zhang, Wanli Feng, Wanli Feng, Jiarong Pan, Jiarong Pan, Tianming Yuan, Tianming Yuan   +9 more
doaj   +1 more source

Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers [PDF]

, 2022
BACKGROUND: Larotrectinib is the first tumour-agnostic therapy that has been approved by the European Medicines Agency. Tumour-agnostic therapies are indicated for a multitude of tumour types.
Kapiteijn, E., Michels, R.E., Krol, M., Arteaga, C.H., Herpen, C.M.L. van, Peters, M.L.   +5 more
core   +2 more sources

Diagnostic challenges and successful organ‐preserving therapy in a case of secretory carcinoma of minor salivary glands

Cancer Reports, 2022
Background Secretory carcinoma is a more recently described subtype of salivary gland carcinoma that may pose diagnostic challenges and frequently harbors NTRK fusions that may successfully be targeted by TRK inhibitors in advanced disease.
Ruben Bill, Daniel G. Deschler, Mikael J. Pittet, Sara I. Pai, Peter M. Sadow, Jong Chul Park   +5 more
doaj   +1 more source

Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. [PDF]

Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children with TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib in the absence of disease progression in a ...
Shukla, Neerav, Van Tilburg, Cornelis M., van Tilburg, Cornelis M, Mascarenhas, Leo, Federman, Noah, Pappo, Alberto S, Perreault, Sébastien, Zhang, Yizhou, Albert, Catherine M., Owens, Cormac, Laetsch, Theodore W, DuBois, Steven G, Albert, Catherine M, Melcon, Soledad Gallego, Zwaan, Christian Michel, Chisholm, Julia, Bernard-Gauthier, Vadim, Schulte, Johannes H., Orbach, Daniel, Goto, Hiroaki, Morgenstern, Daniel A, Schulte, Johannes H, Gallego Melcon, Soledad, De La Cuesta, Esther, Nagasubramanian, Ramamoorthy, Morgenstern, Daniel A., Pappo, Alberto S., Dubois, Steven G., Laetsch, Theodore W., Neu, Natascha, Bielack, Stefan, Geoerger, Birgit   +31 more
core   +3 more sources

Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer:An intra-patient comparative analysis [PDF]

, 2020
Randomized controlled basket trials investigating drugs targeting a rare molecular alteration are challenging. Using patients as their own control overcomes some of these challenges. Growth modulation index (GMI) is the ratio of progression-free survival
Jesus Garcia-Foncillas, Andrew Briggs, Keating, Karen, Hong, David, Childs, Barrett H., Fellous, Marc, David S. Hong, Childs, Barrett H, Marc Fellous, van Tilburg, Cornelis, Hong, David S, Hyman, David M, van Tilburg, Cornelis M, Hong, David S., Alexander Drilon, Childs, Barrett, Lassen, Ulrik, Laetsch, Theodore W, Cornelis M. van Tilburg, David M. Hyman, Reeves, John A., Shivaani Kummar, Gilles Vassal, John A. Reeves, Italiano, Antoine, Drilon, Alexander, Hyman, David, Antoine Italiano, Shivani Nanda, Briggs, Andrew, Theodore W. Laetsch, Reeves, John A, Karen Keating, Nanda, Shivani, Barrett H. Childs, Garcia-Foncillas, Jesus, Laetsch, Theodore, van Tilburg, Cornelis M., Reeves, John, Laetsch, Theodore W., Hyman, David M., Vassal, Gilles, Ulrik Lassen, Kummar, Shivaani   +43 more
core   +1 more source

Larotrectinib in TRK fusion-positive, metastatic non-small cell lung cancer (NSCLC) after treatment with entrectinib in a patient with a history of coronary artery disease

Current Problems in Cancer: Case Reports, 2022
Here, we describe a patient with advanced metastatic non-small cell lung cancer (NSCLC) who harbors a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, identified by liquid biopsy, and has a known history of heart disease.
Derrick W. Su, Janet Pan, Nour Shahab, Hoang Le, Kamini Malhotra, Tushar Patel   +5 more
doaj   +1 more source

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach

Frontiers in Medicine, 2022
There are currently four anti-cancer medicinal products approved for a tissue-agnostic indication. This is an indication based on a common biological characteristic rather than the tissue of origin. To date, the regulatory experience with tissue-agnostic
Jorn Mulder, Odile C. van Stuijvenberg, Paula B. van Hennik, Emile E. Voest, Emile E. Voest, Anna M. G. Pasmooij, Violeta Stoyanova-Beninska, Anthonius de Boer, Anthonius de Boer   +8 more
doaj   +1 more source